These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 31938045)

  • 1. Imaging-assisted anticancer nanotherapy.
    Dasgupta A; Biancacci I; Kiessling F; Lammers T
    Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving nanotherapy delivery and action through image-guided systems pharmacology.
    Ng TSC; Garlin MA; Weissleder R; Miller MA
    Theranostics; 2020; 10(3):968-997. PubMed ID: 31938046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
    Durymanov MO; Rosenkranz AA; Sobolev AS
    Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
    Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
    Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
    Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
    Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
    Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
    Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards tailored management of malignant brain tumors with nanotheranostics.
    Aparicio-Blanco J; Torres-Suárez AI
    Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotheranostics and image-guided drug delivery: current concepts and future directions.
    Lammers T; Kiessling F; Hennink WE; Storm G
    Mol Pharm; 2010 Dec; 7(6):1899-912. PubMed ID: 20822168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting via EPR: Strategies to enhance patient responses.
    Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
    Hou L; Shan X; Hao L; Feng Q; Zhang Z
    Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
    Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
    Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
    Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
    Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.
    Biancacci I; De Lorenzi F; Theek B; Bai X; May JN; Consolino L; Baues M; Moeckel D; Gremse F; von Stillfried S; El Shafei A; Benderski K; Azadkhah Shalmani A; Wang A; Momoh J; Peña Q; Buhl EM; Buyel J; Hennink W; Kiessling F; Metselaar J; Shi Y; Lammers T
    Adv Sci (Weinh); 2022 Apr; 9(10):e2103745. PubMed ID: 35072358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.